Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06735838.2Aexternal-prioritypatent/EP1850874B1/en
Application filed by Genentech, Inc.filedCriticalGenentech, Inc.
Publication of CY1114751T1publicationCriticalpatent/CY1114751T1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Η παρούσα εφεύρεση περιγράφει παράταση χρόνου έως εξέλιξη ασθένειας ή χρόνου επιβίωσης σε καρκινοπαθή, όπου ο καρκίνος του ασθενούς παρουσιάζει ενεργοποίηση HER, υποβάλλοντας τον ασθενή σε θεραπευτική αγωγή με αναστολέα διμερισμού HER, όπως pertuzumab.The present invention describes an extension of time to disease progression or survival time in a cancer patient, wherein the patient's cancer exhibits HER activation, subjecting the patient to treatment with HER dimer inhibitor, such as pertuzumab.
CY20131101129T2005-02-232013-12-13
EXTENSION TIME TO EVALUATION OF Sickness or Survival Time in Cancer Patients Using PERTUZUMAB
CY1114751T1
(en)